Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ: XLO )

1.140 -0.150 (-11.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Unusual volume stocks in Friday's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
Keep an eye on the top gainers and losers in Wednesday's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
These stocks are the most active in today's session
Discover the most active stocks in Wednesday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
Nasdaq Edges Higher; CVS Health Shares Jump Following Upbeat Earnings
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
Crude Oil Down Over 2%; Upstart Shares Jump Following Earnings
Via Benzinga
Exposures Fossil Fuels
Traders are paying attention to the gapping stocks in Wednesday's session.
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
AbbVie and Xilio partner to develop tumor-activated immunotherapies. Xilio's pipeline includes masked T cell engagers for prostate, gastric, and lung cancers. 
Via Benzinga
Dow Dips Over 300 Points; US Inflation Increases More Than Expected
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Wednesday's pre-market session: top gainers and losers
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
From Xilio Therapeutics, Inc.
Via GlobeNewswire
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.